Fabhalta Capsules Specified Drug-use Survey

Last Update: Dec 24, 2025

Fabhalta Capsules Specified Drug-use Survey(C3 Glomerulopathy, CLNP023B11401)

ClinicalTrials.gov Identifier:

Novartis Reference Number:CLNP023B11401

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The objective of this study is to evaluate the safety and effectiveness of Fabhalta in patients with C3 glomerulopathy in clinical practice.

Condition

C3 Glomerulopathy

Overall Status

Recruiting

Number of Participants

Start Date

Sep 17, 2025

Completion Date

Jun 30, 2028

Gender

All

Age(s)

0 Years - 100 Years (Child, Adult, Older Adult)

Eligibility Criteria

Inclusion Criteria:

* All patients who have used Fabhalta for C3 glomerulopathy (including patients with recurrent C3 glomerulopathy post renal transplant).

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Phone: +81337978748

Email: [email protected]

Novartis Pharmaceuticals

Phone: -

Email: -